Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K was filed by Ekso Bionics Holdings, Inc. on July 19, 2017. The filing reports the entry into a material definitive agreement and the announcement of a proposed rights offering. The company is incorporated in Nevada and identifies as an emerging growth company.

Key Financial Metrics and Capital Structure

The filing details a proposed rights offering to raise gross proceeds of up to $34 million. The offering involves the distribution of non-transferable subscription rights to purchase up to 34 million shares of common stock at a subscription price of $1.00 per share. The record date for the offering is set for August 10, 2017. The filing does not provide current revenue, profit, cash flow, margin, or debt figures.

Material Changes and Agreements

  • Purchase Agreement: The Company entered into an agreement with Puissance Capital Management ("Puissance"). Puissance agreed to purchase any unsubscribed shares remaining after the rights offering at $1.00 per share.
  • Ownership Cap: Puissance's aggregate purchase is capped such that it will not own more than 40% of the Company's issued and outstanding common shares following the offering.
  • Registration Rights: A concurrent Registration Rights Agreement requires the Company to file a registration statement for the resale of shares purchased by Puissance.
  • Unregistered Sales: The shares to be purchased by Puissance are unregistered under the Securities Act of 1933, relying on Section 4(2) exemption. Puissance is represented as an accredited investor.

Outlook, Risks, and Management Commentary

Management announced the board's approval of the rights offering to secure capital. The press release accompanying this filing does not constitute an offer to sell securities; the formal offer will be made pursuant to an effective shelf registration statement on Form S-3 and a supplemental prospectus. The filing does not contain specific forward-looking guidance on revenue or earnings, nor does it detail specific risks beyond standard securities law disclosures regarding the unregistered nature of the Puissance shares.

Investor Verification Checklist

  • Verify the final number of shares subscribed by existing shareholders to determine the actual amount Puissance will be required to purchase.
  • Confirm the filing and effectiveness of the supplemental prospectus under Form S-3 (Reg. No. 333-218517) for the public offering.
  • Review the full text of the Purchase Agreement (Exhibit 10.1) for specific conditions precedent to the closing of the rights offering.
  • Assess the dilution impact on existing shareholders given the potential issuance of up to 34 million new shares.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.